[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351333-105":59,"doc-detail-351333-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","erianin-suppresses-lung-adenocarcinoma-by-modulating-mir-494-3pmapkerk-pathway","Erianin suppresses lung adenocarcinoma by modulating miR-494-3p/MAPK/ERK pathway","","Erianin, a natural Dendrobium compound, was investigated for its mechanism against lung adenocarcinoma (LUAD), where the specific pathways involved remained insufficiently defined. LUAD cell proliferation, migration, invasion, and angiogenesis were evaluated using CCK-8, wound healing, colony formation, transwell assays, and tube formation. Cell cycle arrest and apoptosis were assessed by flow cytometry, while miR-494-3p expression was measured by RT-qPCR and related proteins by western blotting in vitro and in vivo. Erianin suppressed LUAD growth and angiogenesis, reduced miR-494-3p, and inhibited the MEGF9/MAPK/ERK/CyclinD1/VEGF-A/Survivin axis, suggesting an anti-tumor cascade action through miR-494-3p regulation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/erianin-suppresses-lung-adenocarcinoma-by-modulating-mir-494-3pmapkerk-pathway/351333/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/erianin-suppresses-lung-adenocarcinoma-by-modulating-mir-494-3pmapkerk-pathway/351333.png","ImageObject",300,407,{"name":92,"@type":93},"\tCallum ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main anti-tumor effect of erianin on lung adenocarcinoma cells?","Question",{"text":112,"@type":113},"Erianin suppresses LUAD cell proliferation and inhibits angiogenesis, invasion, and migration. It also arrests the S phase of the cell cycle.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the effect of erianin on miR-494-3p determined?",{"text":117,"@type":113},"RT-qPCR measured miR-494-3p expression in LUAD cells after erianin treatment.",{"name":119,"@type":110,"acceptedAnswer":120},"Which signaling axis is proposed to mediate erianin’s effect in LUAD?",{"text":121,"@type":113},"The study links erianin’s anti-cancer action to modulation of the MEGF9/MAPK/ERK/CyclinD1/VEGF-A/Survivin axis through downregulation of miR-494-3p.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351333,1790169547,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},137451211410,"https://ap-avatar.wpscdn.com/avatar/2000bb0a9246f588df?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786362646172706240","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nErianin suppresses lung adenocarcinoma by modulating miR-494-3p/MAPK/ERK pathway  \nYiling Ruan1,3, Lingxue Tang2,3, Jialing Zhou1, Chengliang Li1 & Tong Wang1􀀍  \nErianin, a compound naturally occurring in Dendrobium, demonstrates a wide spectrum of biological activities, including antitumor properties as well as immunomodulatory actions. Existing studies have found that erianin has inhibitory effects on a variety of cancer cells, including lung cancer. However, the specific mechanism of action of erianin on lung adenocarcinoma (LUAD) has not been fully revealed. This research endeavors to provide preliminary insights into the suppressive effects of eriolin on the progression of LUAD, with a focus on its antitumor mechanisms. The proliferation of LUAD cells in response to erianin was assessed utilizing Cell Counting Kit-8 (CCK-8), wound closure analysis, and colony-forming assays. The impact of erianin on cellular invasion and migration was assessed utilizing the transwell assay methodology. Tube formation assay was used to evaluate the effect of erianin on tumor angiogenesis. The effect of erianin on cell cycle and apoptosis of LUAD cells was determined by flow cytometry. RT-qPCR was used to detect the expression of miR-494-3p in LUAD cells after erianin treatment. In addition, western blotting was used to detect the effect of erianin on protein expression in LUAD cells in vivo and in vitro. Erianin demonstrated the ability to suppress the proliferation, angiogenesis, invasion and migration of LUAD cells in vitro, and arrested the S phase of the cell cycle. Erianin can downregulate the expression of miR-494-3p and exert its anti-cancer effect by affecting the MEGF9/MAPK/ERK/CyclinD1/VEGF-A/Survivin axis in LUAD cells. Our study preliminarily revealed that erianin may exert anti-tumor effects by downregulating the expression of miR-494-3p, thereby regulating the MEGF9/MAPK/ERK/CyclinD1/VEGF-A/Survivin cascade reaction.  \nKeywords Erianin, Lung adenocarcinoma, MiRNA, MAPK signaling pathway  \nLung cancer, a devastating condition arising in the lungs, occupies a prominent position globally as one of the most prevalent malignant chest tumors. Its incidence and mortality rates have been experiencing a significant and rapid increase in recent years, posing a significant global risk to public health. The alarming pattern highlights the pressing requirement for thorough research, early diagnostic techniques, and efficacious therapeutic approaches to counteract this fatal illness. Based on the most recent information released by GLOBALCAN, it is estimated that there will be 2,480,301 new cases and 1,817,172 deaths of lung cancer worldwide in 2022, ranking first among 36 types of cancer in the world (12.4% and 18.7%)1. Currently, the surge in smoking rates among females, coupled with alterations in cigarette composition, environmental contaminants, and a myriad of other factors, has led to lung adenocarcinoma overtaking squamous cell carcinoma as the most prevalent subtype of non-small cell lung cancer2. The early treatment of lung adenocarcinoma mainly relies on surgery, while the middle and late stages include surgery, chemotherapy, radiotherapy, targeted and immunotherapy, etc. Targeted therapy drugs such as gefitinib, erlotinib, crizotinib, etc.3. Over recent years, clinical practice has incorporated various targeted therapeutic agents, including gefitinib, erlotinib, crizotinib, among others, that are specifically designed to address particular molecular markers such as EGFR, ALK, and ROS14. They are usually less toxic to normal cells and have low side effects. However, due to their substantial medical expenses and the inevitable emergence of drug resistance in nearly all patients, the population that can derive benefit from these treatments is constrained5. Therefore, exploring new therapeutic drugs has important clinical value and practical significanc","cbCaidar5ogsZoFA","https://ap.wps.com/l/cbCaidar5ogsZoFA","pdf",2711080,13,"English","# Background\n## Lung cancer and LUAD treatment challenges\n## MicroRNAs and miR-494-3p relevance\n## MAPK signaling overview\n# Experimental design and methods\n## Cell proliferation assays (CCK-8, colony formation)\n## Migration and invasion assays (wound healing, transwell)\n## Angiogenesis assay (tube formation)\n## Cell cycle and apoptosis (flow cytometry)\n## Molecular analyses (RT-qPCR, western blotting)\n# Findings and mechanism\n## Erianin effects on LUAD malignant behaviors\n## miR-494-3p downregulation and pathway modulation\n## MEGF9/MAPK/ERK/CyclinD1/VEGF-A/Survivin axis regulation","[{\"question\":\"What is the main anti-tumor effect of erianin on lung adenocarcinoma cells?\",\"answer\":\"Erianin suppresses LUAD cell proliferation and inhibits angiogenesis, invasion, and migration. It also arrests the S phase of the cell cycle.\"},{\"question\":\"How was the effect of erianin on miR-494-3p determined?\",\"answer\":\"RT-qPCR measured miR-494-3p expression in LUAD cells after erianin treatment.\"},{\"question\":\"Which signaling axis is proposed to mediate erianin’s effect in LUAD?\",\"answer\":\"The study links erianin’s anti-cancer action to modulation of the MEGF9/MAPK/ERK/CyclinD1/VEGF-A/Survivin axis through downregulation of miR-494-3p.\"}]","Erianin suppresses lung adenocarcinoma by modulating miR-494-3p/MAPK/ERK pathway | PDF",1790093580,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/87014199acc2f59991a9ff281f17e688.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a52ffc747a35570f96ca34dcfb687a0e.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e820fb183b29297b2de140e7441ac819.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8c1a22d5085a5e7c094bdb4f122323c0.webp",980,1287]